Admedus is developing a range of therapeutic vaccines through the company's investment in the research & development of immunotherapies based on Professor Ian Frazer’s next-generation vaccine technology.

Admedus Immunotherapies is focused on developing DNA vaccines for the treatment and prevention of infectious diseases and cancers.

Working with immunologist Professor Ian Frazer, the creator of the world’s first prophylactic cervical cancer vaccine Gardasil®, Admedus is currently investigating the commercialisation of therapeutic vaccines (aimed at both preventing the spread of the virus and offering a treatment to those infected) for both Herpes Simplex Virus 2 (HSV-2) and Human Papillomavirus (HPV).

The Admedus HSV-2 therapeutic vaccine is currently in a Phase II clinical trial and has achieved successful results to date. The HPV therapeutic vaccine is on track to enter a Phase Ib clinical trial in 2016, following the expected successful completion of pre-clinical studies. 


How it works

DNA vaccine technology is used to stimulate humoral (antibody) and/or cellular (T-cell) immune responses that have an enhanced ability to destroy infected or cancerous cells.